In brief
- On September 14, the FDA will hold a public hearing, both in person and online, on how psychedelic therapy should be implemented if such medications are eventually approved.
- The session will not debate the efficacy of any specific drug or its legal scheduling: the focus is strictly on provider training, safety, access, and data collection.
- Anyone wishing to speak must register by August 21; written comments will be accepted until October 5 and carry equal weight.
The Food and Drug Administration (FDA) has published a notice in the Federal Register convening a public hearing on the potential future therapeutic use of psychedelics. The event will take place on September 14 from 12:30 to 4:30 p.m. Eastern Time at the agency’s White Oak campus in Silver Spring, Maryland, with options to attend and participate remotely.
Consulting on the “how,” not the “if”
Perhaps the most telling aspect of the notice, published on July 14 under Docket No. FDA-2026-N-7542, is what the agency explicitly excludes: it will not accept comments on the safety or efficacy of any specific investigational drug, the scheduling of any substance under the Controlled Substances Act, legalization or decriminalization, or religious, ceremonial, or personal use outside healthcare settings. The question is not whether psychedelics should be used clinically, but how to roll them out responsibly once approved medications exist.
The four core discussion topics make this focus evident: training and credentialing for facilitators; patient safety, including pre-screening, crisis management, and informed consent for challenging experiences; terms of access, encompassing insurance coverage and real-world clinic capacity; and data standardization, linking health records, federal surveys, and state programs to track both medical and non-medical use.
Priority vouchers and an executive order in the mix
The document itself places the hearing within a broader landscape. In April 2026, the FDA granted national priority vouchers—which shorten review timelines—to companies researching psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for post-traumatic stress disorder. The agency clarifies that neither these vouchers nor the Breakthrough Therapy designations previously awarded to MDMA for PTSD (2017) and psilocybin for depression (2018 and 2019) represent a determination that a drug is safe or effective. All of this unfolds under Executive Order 14401, signed on April 18, 2026, which directs federal agencies to coordinate efforts to facilitate research and share data on these compounds.
What it means
A regulator seeking input on provider credentials, insurance reimbursement, and data registries before any psychedelic has been formally approved signals the direction of travel, even if it does not speed up any specific decision: ongoing applications for psilocybin and MDMA-related compounds remain bound to their own clinical trial timelines, entirely independent of this hearing. And because the FDA insists it will not touch scheduling or non-medical use, nothing changes for those using these substances outside clinical trials today. The very agency that recently finalized clinical trial guidance for psychedelics is now outlining the next step forward.
What is at stake here is what prescription psychedelic treatment will look like in the years ahead: who will be qualified to facilitate sessions and who will actually have access beyond those who can pay out of pocket. Crucially, a federal agency talking openly about preparation, setting, facilitation, and navigating difficult experiences reflects an adoption, in regulatory language, of principles long developed by psychonaut culture and harm reduction networks.
Source
- U.S. Food and Drug Administration. Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments. Federal Register, Docket No. FDA-2026-N-7542 (91 FR 43095), July 14, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
